Scholarlink

Objectives <p>To assess the efficacy and tolerability of transarterial chemoembolization (TACE) plus immune checkpoint inhibitors (ICIs) plus molecular targeted therapies (MTT) in elderly patients with hepatocellular carcinoma (HCC) (≥ 65 years).</p> Methods <p>This retrospective, multicenter study enrolled treatment-naïve HCC patients undergoing TACE combined with ICIs and MTT at three Chinese medical centers from June 2019 to December 2023. The study’s primary endpoint was overall survival (OS), with secondary endpoints being the objective response rate (ORR), disease control rate (DCR) per modified RECIST criteria, and adverse events (AEs). To minimize selection bias, propensity score matching (PSM) was utilized for the elderly and younger patient cohorts.</p> Results <p>The study cohort comprised 317 patients, with a median OS of 30.8 months for the overall population. The elderly patients had comparable OS (median, 33.3 vs. 30.4 months, <i>P</i> = 0.219) than younger patients. The PSM cohort included 106 elderly patients and 106 younger patients. After PSM, the elderly patients also had similar OS compared with younger patients (median, 33.3 vs. 24.6 months, <i>P</i> = 0.141). Meanwhile, the elderly patients achieved a similar ORR and DCR (58.5% vs. 54.7%, <i>P</i> = 0.579; 90.1% vs. 85.8%, <i>P</i> = 0.287, respectively) versus younger patients. No obvious differences in grade 3/4 AEs were noted among the two groups, and no new safety concerns arose.</p> Conclusions <p>Elderly patients (age ≥ 65 years) receiving TACE combined with ICIs and MTT showed similar trends in prognosis and safety profiles compared with younger patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月4日

查看全文
  • Xin Hong,
  • Jin-Tao Huang,
  • Di Hu,
  • Wen-Jie Zhou,
  • Jian Shen,
  • Xiao-Li Zhu

摘要

Objectives

To assess the efficacy and tolerability of transarterial chemoembolization (TACE) plus immune checkpoint inhibitors (ICIs) plus molecular targeted therapies (MTT) in elderly patients with hepatocellular carcinoma (HCC) (≥ 65 years).

Methods

This retrospective, multicenter study enrolled treatment-naïve HCC patients undergoing TACE combined with ICIs and MTT at three Chinese medical centers from June 2019 to December 2023. The study’s primary endpoint was overall survival (OS), with secondary endpoints being the objective response rate (ORR), disease control rate (DCR) per modified RECIST criteria, and adverse events (AEs). To minimize selection bias, propensity score matching (PSM) was utilized for the elderly and younger patient cohorts.

Results

The study cohort comprised 317 patients, with a median OS of 30.8 months for the overall population. The elderly patients had comparable OS (median, 33.3 vs. 30.4 months, P = 0.219) than younger patients. The PSM cohort included 106 elderly patients and 106 younger patients. After PSM, the elderly patients also had similar OS compared with younger patients (median, 33.3 vs. 24.6 months, P = 0.141). Meanwhile, the elderly patients achieved a similar ORR and DCR (58.5% vs. 54.7%, P = 0.579; 90.1% vs. 85.8%, P = 0.287, respectively) versus younger patients. No obvious differences in grade 3/4 AEs were noted among the two groups, and no new safety concerns arose.

Conclusions

Elderly patients (age ≥ 65 years) receiving TACE combined with ICIs and MTT showed similar trends in prognosis and safety profiles compared with younger patients.